Concord Biotech (CONCORDBIO)
STALWARTFairStock Score: 70/100 — STEADY
Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹1,051.1 |
| Market Cap | ₹12,769.45 Cr |
| P/E Ratio | 40.2 |
| ROCE | 28.35% |
| ROE | 17.39% |
| Dividend Yield | 0.88% |
| Profit Growth | -3.98% |
| Debt/Equity | 0 |
| Sales Growth | 6.42% |
| Free Cash Flow | ₹8,500 Cr |
| Promoter Holding | 44.08% |
| 52-Week Range | ₹987 — ₹2,146 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹173.27 |
Concord Biotech trades with a P/E ratio of 40.2, ROCE of 28.35%, ROE of 17.39%, profit growth of -3.98%, debt-to-equity of 0. The FairStock Score of 70/100 reflects strong fundamentals across multiple dimensions.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer